Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2008

Open Access 01-12-2008 | Research article

Low-penetrance alleles predisposing to sporadic colorectal cancers: a French case-controlled genetic association study

Authors: Sébastien Küry, Bruno Buecher, Sébastien Robiou-du-Pont, Catherine Scoul, Hélène Colman, Tanguy Le Neel, Claire Le Houérou, Roger Faroux, Jean Ollivry, Bernard Lafraise, Louis-Dominique Chupin, Véronique Sébille, Stéphane Bézieau

Published in: BMC Cancer | Issue 1/2008

Login to get access

Abstract

Background

Sporadic colorectal cancers (CRC) are multifactorial diseases resulting from the combined effects of numerous genetic, environmental and behavioral risk factors. Genetic association studies have suggested low-penetrance alleles of extremely varied genes to be involved in susceptibility to CRC in Caucasian populations.

Methods

Through a large genetic association study based on 1023 patients with sporadic CRC and 1121 controls, we tested a panel of these low-penetrance alleles to find out whether they could determine "genotypic profiles" at risk for CRC among individuals of the French population. We examined 52 polymorphisms of 35 genes – drawn from inflammation, xenobiotic detoxification, one-carbon, insulin signaling, and DNA repair pathways – for their possible contribution to colorectal carcinogenesis. The risk of cancer associated with these polymorphisms was assessed by calculation of odds ratios (OR) using multivariate analyses and logistic regression.

Results

Whereas all these polymorphisms had previously been found to be associated with CRC risk, especially in Caucasian populations, we were able to replicate the association for only five of them. Three SNPs were shown to increase CRC risk: PTGS1 c.639C>A (p.Gly213Gly), IL8 c.-352T>A, and MTHFR c.1286A>C (p.Ala429Glu). On the contrary, two other SNPs, PLA2G2A c.435+230C>T and PPARG c.1431C>T (p.His477His), were associated with a decrease in CRC risk. Further analyses highlighted genotypic combinations having a greater predisposing effect on CRC (OR 1.97, 95%CI 1.31–2.97, p = 0.0009) than the allelic variants that were examined separately.

Conclusion

The identification of CRC-predisposing combinations, composed of alleles PTGS1 c.639A, PLA2G2A c.435+230C, PPARG c.1431C, IL8 c.-352A, and MTHFR c.1286C, highlights the importance of inflammatory processes in susceptibility to sporadic CRC, as well as a possible crosstalk between inflammation and one-carbon pathways.
Appendix
Available only for authorised users
Literature
1.
Remontet L, Esteve J, Bouvier AM, Grosclaude P, Launoy G, Menegoz F, Exbrayat C, Tretare B, Carli PM, Guizard AV, Troussard X, Bercelli P, Colonna M, Halna JM, Hedelin G, Mace-Lesec'h J, Peng J, Buemi A, Velten M, Jougla E, Arveux P, Le Bodic L, Michel E, Sauvage M, Schvartz C, Faivre J: Cancer incidence and mortality in France over the period 1978–2000. Rev Epidemiol Sante Publique. 2003, 51 (1 Pt 1): 3-30.PubMed
2.
de la Chapelle A: Genetic predisposition to colorectal cancer. Nat Rev Cancer. 2004, 4 (10): 769-780. 10.1038/nrc1453.CrossRefPubMed
3.
Davidson NO: Genetic testing in colorectal cancer: who, when, how and why. Keio J Med. 2007, 56 (1): 14-20. 10.2302/kjm.56.14.CrossRefPubMed
4.
Hunter DJ, Riboli E, Haiman CA, Albanes D, Altshuler D, Chanock SJ, Haynes RB, Henderson BE, Kaaks R, Stram DO, Thomas G, Thun MJ, Blanche H, Buring JE, Burtt NP, Calle EE, Cann H, Canzian F, Chen YC, Colditz GA, Cox DG, Dunning AM, Feigelson HS, Freedman ML, Gaziano JM, Giovannucci E, Hankinson SE, Hirschhorn JN, Hoover RN, Key T, et al: A candidate gene approach to searching for low-penetrance breast and prostate cancer genes. Nat Rev Cancer. 2005, 5 (12): 977-985. 10.1038/nrc1754.CrossRefPubMed
5.
Goodman JE, Mechanic LE, Luke BT, Ambs S, Chanock S, Harris CC: Exploring SNP-SNP interactions and colon cancer risk using polymorphism interaction analysis. Int J Cancer. 2006, 118 (7): 1790-1797. 10.1002/ijc.21523.CrossRefPubMedPubMedCentral
6.
Tabor HK, Risch NJ, Myers RM: Candidate-gene approaches for studying complex genetic traits: practical considerations. Nat Rev Genet. 2002, 3 (5): 391-397. 10.1038/nrg796.CrossRefPubMed
7.
Naccarati A, Pardini B, Hemminki K, Vodicka P: Sporadic colorectal cancer and individual susceptibility: a review of the association studies investigating the role of DNA repair genetic polymorphisms. Mutat Res. 2007, 635 (2–3): 118-145.CrossRefPubMed
8.
Tomlinson I, Webb E, Carvajal-Carmona L, Broderick P, Kemp Z, Spain S, Penegar S, Chandler I, Gorman M, Wood W, Barclay E, Lubbe S, Martin L, Sellick G, Jaeger E, Hubner R, Wild R, Rowan A, Fielding S, Howarth K, Silver A, Atkin W, Muir K, Logan R, Kerr D, Johnstone E, Sieber O, Gray R, Thomas H, Peto J, et al: A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21. Nat Genet. 2007, 39 (8): 984-988. 10.1038/ng2085.CrossRefPubMed
9.
Zanke BW, Greenwood CM, Rangrej J, Kustra R, Tenesa A, Farrington SM, Prendergast J, Olschwang S, Chiang T, Crowdy E, Ferretti V, Laflamme P, Sundararajan S, Roumy S, Olivier JF, Robidoux F, Sladek R, Montpetit A, Campbell P, Bézieau S, O'Shea AM, Zogopoulos G, Cotterchio M, Newcomb P, McLaughlin J, Younghusband B, Green R, Green J, Porteous ME, Campbell H, et al: Genome-wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24. Nat Genet. 2007, 39 (8): 989-994. 10.1038/ng2089.CrossRefPubMed
10.
Picelli S, Vandrovcova J, Jones S, Djureinovic T, Skoglund J, Zhou XL, Velculescu VE, Vogelstein B, Lindblom A: Genome-wide linkage scan for colorectal cancer susceptibility genes supports linkage to chromosome 3q. BMC Cancer. 2008, 8 (1): 87-10.1186/1471-2407-8-87.CrossRefPubMedPubMedCentral
11.
Tenesa A, Farrington SM, Prendergast JG, Porteous ME, Walker M, Haq N, Barnetson RA, Theodoratou E, Cetnarskyj R, Cartwright N, Semple C, Clark AJ, Reid FJ, Smith LA, Kavoussanakis K, Koessler T, Pharoah PD, Buch S, Schafmayer C, Tepel J, Schreiber S, Volzke H, Schmidt CO, Hampe J, Chang-Claude J, Hoffmeister M, Brenner H, Wilkening S, Canzian F, Capella G, et al: Genome-wide association scan identifies a colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21. Nat Genet. 2008, 40 (5): 631-637. 10.1038/ng.133.CrossRefPubMedPubMedCentral
12.
Tomlinson IP, Webb E, Carvajal-Carmona L, Broderick P, Howarth K, Pittman AM, Spain S, Lubbe S, Walther A, Sullivan K, Jaeger E, Fielding S, Rowan A, Vijayakrishnan J, Domingo E, Chandler I, Kemp Z, Qureshi M, Farrington SM, Tenesa A, Prendergast JG, Barnetson RA, Penegar S, Barclay E, Wood W, Martin L, Gorman M, Thomas H, Peto J, Bishop DT, et al: A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. Nat Genet. 2008, 40 (5): 623-630. 10.1038/ng.111.CrossRefPubMed
13.
Onay VU, Briollais L, Knight JA, Shi E, Wang Y, Wells S, Li H, Rajendram I, Andrulis IL, Ozcelik H: SNP-SNP interactions in breast cancer susceptibility. BMC Cancer. 2006, 6: 114-10.1186/1471-2407-6-114.CrossRefPubMedPubMedCentral
14.
Wu X, Gu J, Grossman HB, Amos CI, Etzel C, Huang M, Zhang Q, Millikan RE, Lerner S, Dinney CP, Spitz MR: Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-cycle-control genes. Am J Hum Genet. 2006, 78 (3): 464-479. 10.1086/500848.CrossRefPubMedPubMedCentral
15.
Küry S, Buecher B, Robiou-du-Pont S, Scoul C, Sebille V, Colman H, Le Houérou C, Le Neel T, Bourdon J, Faroux R, Ollivry J, Lafraise B, Chupin LD, Bézieau S: Combinations of cytochrome P450 gene polymorphisms enhancing the risk for sporadic colorectal cancer related to red meat consumption. Cancer Epidemiol Biomarkers Prev. 2007, 16 (7): 1460-1467. 10.1158/1055-9965.EPI-07-0236.CrossRefPubMed
16.
Goodman JE, Bowman ED, Chanock SJ, Alberg AJ, Harris CC: Arachidonate lipoxygenase (ALOX) and cyclooxygenase (COX) polymorphisms and colon cancer risk. Carcinogenesis. 2004, 25 (12): 2467-2472. 10.1093/carcin/bgh260.CrossRefPubMed
17.
Landi S, Moreno V, Gioia-Patricola L, Guino E, Navarro M, de Oca J, Capella G, Canzian F: Association of common polymorphisms in inflammatory genes interleukin (IL)6, IL8, tumor necrosis factor alpha, NFKB1, and peroxisome proliferator-activated receptor gamma with colorectal cancer. Cancer Res. 2003, 63 (13): 3560-3566.PubMed
18.
Yamada Y, Hamajima N, Kato T, Iwata H, Yamamura Y, Shinoda M, Suyama M, Mitsudomi T, Tajima K, Kusakabe S, Yoshida H, Banno Y, Akao Y, Tanaka M, Nozawa Y: Association of a polymorphism of the phospholipase D2 gene with the prevalence of colorectal cancer. J Mol Med. 2003, 81 (2): 126-131.PubMed
19.
de Jong MM, Nolte IM, te Meerman GJ, Graaf van der WT, de Vries EG, Sijmons RH, Hofstra RM, Kleibeuker JH: Low-penetrance genes and their involvement in colorectal cancer susceptibility. Cancer Epidemiol Biomarkers Prev. 2002, 11 (11): 1332-1352.PubMed
20.
Landi S, Gemignani F, Moreno V, Gioia-Patricola L, Chabrier A, Guino E, Navarro M, de Oca J, Capella G, Canzian F: A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of colorectal cancer. Pharmacogenet Genomics. 2005, 15 (8): 535-546.CrossRefPubMed
21.
Sachse C, Smith G, Wilkie MJ, Barrett JH, Waxman R, Sullivan F, Forman D, Bishop DT, Wolf CR: A pharmacogenetic study to investigate the role of dietary carcinogens in the etiology of colorectal cancer. Carcinogenesis. 2002, 23 (11): 1839-1849. 10.1093/carcin/23.11.1839.CrossRefPubMed
22.
Logt van der EM, Bergevoet SM, Roelofs HM, van Hooijdonk Z, Te Morsche RH, Wobbes T, de Kok JB, Nagengast FM, Peters WH: Genetic polymorphisms in UDP-glucuronosyltransferases and glutathione S-transferases and colorectal cancer risk. Carcinogenesis. 2004, 25 (12): 2407-2415. 10.1093/carcin/bgh251.CrossRefPubMed
23.
Innocenti F, Grimsley C, Das S, Ramirez J, Cheng C, Kuttab-Boulos H, Ratain MJ, Di Rienzo A: Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups. Pharmacogenetics. 2002, 12 (9): 725-733. 10.1097/00008571-200212000-00006.CrossRefPubMed
24.
Le Marchand L, Donlon T, Seifried A, Kaaks R, Rinaldi S, Wilkens LR: Association of a common polymorphism in the human GH1 gene with colorectal neoplasia. J Natl Cancer Inst. 2002, 94 (6): 454-460.CrossRefPubMed
25.
Slattery ML, Samowitz W, Hoffman M, Ma KN, Levin TR, Neuhausen S: Aspirin, NSAIDs, and colorectal cancer: possible involvement in an insulin-related pathway. Cancer Epidemiol Biomarkers Prev. 2004, 13 (4): 538-545.PubMed
26.
Le Marchand L, Donlon T, Hankin JH, Kolonel LN, Wilkens LR, Seifried A: B-vitamin intake, metabolic genes, and colorectal cancer risk (United States). Cancer Causes Control. 2002, 13 (3): 239-248. 10.1023/A:1015057614870.CrossRefPubMed
27.
Sharp L, Little J: Polymorphisms in genes involved in folate metabolism and colorectal neoplasia: a HuGE review. Am J Epidemiol. 2004, 159 (5): 423-443. 10.1093/aje/kwh066.CrossRefPubMed
28.
Chen J, Kyte C, Valcin M, Chan W, Wetmur JG, Selhub J, Hunter DJ, Ma J: Polymorphisms in the one-carbon metabolic pathway, plasma folate levels and colorectal cancer in a prospective study. Int J Cancer. 2004, 110 (4): 617-620. 10.1002/ijc.20148.CrossRefPubMed
29.
Hansen R, Saebo M, Skjelbred CF, Nexo BA, Hagen PC, Bock G, Bowitz Lothe IM, Johnson E, Aase S, Hansteen IL, Vogel U, Kure EH: GPX Pro198Leu and OGG1 Ser326Cys polymorphisms and risk of development of colorectal adenomas and colorectal cancer. Cancer Lett. 2005, 229 (1): 85-91. 10.1016/j.canlet.2005.04.019.CrossRefPubMed
30.
Küry S, Buecher B, Robiou-du-Pont S, Scoul C, Colman H, Lelièvre B, Olschwang S, Le Houérou C, Le Neel T, Faroux R, Ollivry J, Lafraise B, Chupin LD, Bézieau S: The thorough screening of the MUTYH gene in a large French cohort of sporadic colorectal cancers. Genet Test. 2007, 11 (4): 373-9. 10.1089/gte.2007.0029.CrossRefPubMed
31.
Cox DG, Pontes C, Guino E, Navarro M, Osorio A, Canzian F, Moreno V: Polymorphisms in prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) and risk of colorectal cancer. Br J Cancer. 2004, 91 (2): 339-343.PubMedPubMedCentral
32.
Halushka MK, Walker LP, Halushka PV: Genetic variation in cyclooxygenase 1: effects on response to aspirin. Clin Pharmacol Ther. 2003, 73 (1): 122-130. 10.1067/mcp.2003.1.CrossRefPubMed
33.
Jiang J, Gajalakshmi V, Wang J, Kuriki K, Suzuki S, Nakamura S, Akasaka S, Ishikawa H, Tokudome S: Influence of the C161T but not Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma on colorectal cancer in an Indian population. Cancer Sci. 2005, 96 (8): 507-512. 10.1111/j.1349-7006.2005.00072.x.CrossRefPubMed
34.
Ulrich CM, Bigler J, Sparks R, Whitton J, Sibert JG, Goode EL, Yasui Y, Potter JD: Polymorphisms in PTGS1 (= COX-1) and risk of colorectal polyps. Cancer Epidemiol Biomarkers Prev. 2004, 13 (5): 889-893.PubMed
35.
den Dunnen JT, Antonarakis SE: Nomenclature for the description of human sequence variations. Hum Genet. 2001, 109 (1): 121-124. 10.1007/s004390100505.CrossRefPubMed
36.
37.
38.
Ye Z, Parry JM: A meta-analysis of 20 case-control studies of the glutathione S-transferase M1 (GSTM1) status and colorectal cancer risk. Med Sci Monit. 2003, 9 (10): SR83-91.PubMed
39.
Brennan P: Gene-environment interaction and aetiology of cancer: what does it mean and how can we measure it?. Carcinogenesis. 2002, 23 (3): 381-387. 10.1093/carcin/23.3.381.CrossRefPubMed
40.
Sole X, Guino E, Valls J, Iniesta R, Moreno V: SNPStats: a web tool for the analysis of association studies. Bioinformatics. 2006, 22 (15): 1928-1929. 10.1093/bioinformatics/btl268.CrossRefPubMed
41.
Diaz BL, Arm JP: Phospholipase A(2). Prostaglandins Leukot Essent Fatty Acids. 2003, 69 (2–3): 87-97. 10.1016/S0952-3278(03)00069-3.CrossRefPubMed
42.
Steele VE, Hawk ET, Viner JL, Lubet RA: Mechanisms and applications of non-steroidal anti-inflammatory drugs in the chemoprevention of cancer. Mutat Res. 2003, 523-524: 137-144.CrossRefPubMed
43.
Tan W, Wu J, Zhang X, Guo Y, Liu J, Sun T, Zhang B, Zhao D, Yang M, Yu D, Lin D: Associations of functional polymorphisms in cyclooxygenase-2 and platelet 12-lipoxygenase with risk of occurrence and advanced disease status of colorectal cancer. Carcinogenesis. 2007, 28 (6): 1197-1201. 10.1093/carcin/bgl242.CrossRefPubMed
44.
MacPhee M, Chepenik KP, Liddell RA, Nelson KK, Siracusa LD, Buchberg AM: The secretory phospholipase A2 gene is a candidate for the Mom1 locus, a major modifier of ApcMin-induced intestinal neoplasia. Cell. 1995, 81 (6): 957-966. 10.1016/0092-8674(95)90015-2.CrossRefPubMed
45.
46.
Auwerx J: Nuclear receptors. I. PPAR gamma in the gastrointestinal tract: gain or pain?. Am J Physiol Gastrointest Liver Physiol. 2002, 282 (4): G581-585.CrossRefPubMed
47.
Michalik L, Desvergne B, Wahli W: Peroxisome-proliferator-activated receptors and cancers: complex stories. Nat Rev Cancer. 2004, 4 (1): 61-70. 10.1038/nrc1254.CrossRefPubMed
48.
Siezen CL, van Leeuwen AI, Kram NR, Luken ME, van Kranen HJ, Kampman E: Colorectal adenoma risk is modified by the interplay between polymorphisms in arachidonic acid pathway genes and fish consumption. Carcinogenesis. 2005, 26 (2): 449-457. 10.1093/carcin/bgh336.CrossRefPubMed
49.
Gong Z, Xie D, Deng Z, Bostick RM, Muga SJ, Hurley TG, Hebert JR: The PPAR{gamma} Pro12Ala polymorphism and risk for incident sporadic colorectal adenomas. Carcinogenesis. 2005, 26 (3): 579-585. 10.1093/carcin/bgh343.CrossRefPubMed
50.
Theodoropoulos G, Papaconstantinou I, Felekouras E, Nikiteas N, Karakitsos P, Panoussopoulos D, Lazaris A, Patsouris E, Bramis J, Gazouli M: Relation between common polymorphisms in genes related to inflammatory response and colorectal cancer. World J Gastroenterol. 2006, 12 (31): 5037-5043.CrossRefPubMedPubMedCentral
51.
Gunter MJ, Canzian F, Landi S, Chanock SJ, Sinha R, Rothman N: Inflammation-related gene polymorphisms and colorectal adenoma. Cancer Epidemiol Biomarkers Prev. 2006, 15 (6): 1126-1131. 10.1158/1055-9965.EPI-06-0042.CrossRefPubMed
52.
Lee WP, Tai DI, Lan KH, Li AF, Hsu HC, Lin EJ, Lin YP, Sheu ML, Li CP, Chang FY, Chao Y, Yen SH, Lee SD: The -251T allele of the interleukin-8 promoter is associated with increased risk of gastric carcinoma featuring diffuse-type histopathology in Chinese population. Clin Cancer Res. 2005, 11 (18): 6431-6441. 10.1158/1078-0432.CCR-05-0942.CrossRefPubMed
53.
Ulrich CM, Potter JD: Folate and cancer – timing is everything. Jama. 2007, 297 (21): 2408-2409. 10.1001/jama.297.21.2408.CrossRefPubMed
54.
Huang Y, Han S, Li Y, Mao Y, Xie Y: Different roles of MTHFR C677T and A1298C polymorphisms in colorectal adenoma and colorectal cancer: a meta-analysis. J Hum Genet. 2007, 52 (1): 73-85. 10.1007/s10038-006-0082-5.CrossRefPubMed
55.
Hubner RA, Houlston RS: MTHFR C677T and colorectal cancer risk: A meta-analysis of 25 populations. Int J Cancer. 2007, 120 (5): 1027-1035. 10.1002/ijc.22440.CrossRefPubMed
56.
Mu LN, Cao W, Zhang ZF, Cai L, Jiang QW, You NC, Goldstein BY, Wei GR, Chen CW, Lu QY, Zhou XF, Ding BG, Chang J, Yu SZ: Methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C polymorphisms and the risk of primary hepatocellular carcinoma (HCC) in a Chinese population. Cancer Causes Control. 2007, 18 (6): 665-675. 10.1007/s10552-007-9012-x.CrossRefPubMedPubMedCentral
57.
Araki A, Hosoi T, Orimo H, Ito H: Association of plasma homocysteine with serum interleukin-6 and C-peptide levels in patients with type 2 diabetes. Metabolism. 2005, 54 (6): 809-814. 10.1016/j.metabol.2005.02.001.CrossRefPubMed
58.
Dedoussis GV, Panagiotakos DB, Pitsavos C, Chrysohoou C, Skoumas J, Choumerianou D, Stefanadis C: An association between the methylenetetrahydrofolate reductase (MTHFR) C677T mutation and inflammation markers related to cardiovascular disease. Int J Cardiol. 2005, 100 (3): 409-414. 10.1016/j.ijcard.2004.08.038.CrossRefPubMed
59.
Chanock SJ, Manolio T, Boehnke M, Boerwinkle E, Hunter DJ, Thomas G, Hirschhorn JN, Abecasis G, Altshuler D, Bailey-Wilson JE, Brooks LD, Cardon LR, Daly M, Donnelly P, Fraumeni JF, Freimer NB, Gerhard DS, Gunter C, Guttmacher AE, Guyer MS, Harris EL, Hoh J, Hoover R, Kong CA, Merikangas KR, Morton CC, Palmer LJ, Phimister EG, Rice JP, Roberts J, et al: Replicating genotype-phenotype associations. Nature. 2007, 447 (7145): 655-660. 10.1038/447655a.CrossRefPubMed
60.
Ioannidis JP, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG: Replication validity of genetic association studies. Nat Genet. 2001, 29 (3): 306-309. 10.1038/ng749.CrossRefPubMed
Metadata
Title
Low-penetrance alleles predisposing to sporadic colorectal cancers: a French case-controlled genetic association study
Authors
Sébastien Küry
Bruno Buecher
Sébastien Robiou-du-Pont
Catherine Scoul
Hélène Colman
Tanguy Le Neel
Claire Le Houérou
Roger Faroux
Jean Ollivry
Bernard Lafraise
Louis-Dominique Chupin
Véronique Sébille
Stéphane Bézieau
Publication date
01-12-2008
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2008
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-8-326

Other articles of this Issue 1/2008

BMC Cancer 1/2008 Go to the issue

Research article

Heat shock protein90 in lobular neoplasia of the breast

Research article

Thymostimulin in advanced hepatocellular carcinoma: A phase II trial

Research article

A haplotype variation affecting the mitochondrial transportation of hMYH protein could be a risk factor for colorectal cancer in Chinese

Research article

Incidence, mortality and survival patterns of prostate cancer among residents in Singapore from 1968 to 2002

Research article

Bioinformatic identification of FGF, p38-MAPK, and calcium signalling pathways associated with carcinoma in situin the urinary bladder

Research article

Genetic analysis of the vitamin D receptor gene in two epithelial cancers: melanoma and breast cancer case-control studies
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits